Iatrogénie médicamenteuse : évaluer les risques et les coûts

Value of the Information & Strength of the Argument

The value of the information is high: it consolidates existing national data into a coherent overview of drug safety in France. The argumentation is solid, based on multiple sources that include hospital studies, real-world pharmacovigilance reports, and population-level data from the SNDS. The speakers emphasize that iatrogenesis is not always an error and that most events are not avoidable, which nuances the discourse on medication risk. They argue for strengthening public expertise rather than creating new structures, and they support their claims with specific figures (e.g., 212,500 hospitalizations, 71% of errors during administration, 15 million euros budget for centers). The presentation is well-structured and grounded in a formal report, though it does not provide a full methodological breakdown or external validation of the estimates.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is commendable: the report relies on established national surveillance systems and peer-reviewed studies like Yathrostat. The quality of sources is good, with references to the national pharmacovigilance database, the HAS, and the SNDS, all of which are recognized institutional sources. The title accurately matches the content: the hearing systematically assesses risks (hospitalizations, deaths, errors) and costs (budgetary constraints, economic implications). No conflicting sources were presented, and the speakers consistently referenced prior senatorial reports, particularly on opioids. The adequacy of title to content is strong, though the discussion on costs is more implicit than explicit, focusing on resource allocation rather than precise economic calculations.

The title accurately reflects the content: the hearing focuses on evaluating the risks and costs of drug iatrogenesis, with quantified estimates and discussion of economic implications.

8/10

The hearing presents a formal report from the Haut Conseil de la Santé Publique, based on multiple national data sources including Yathrostat, pharmacovigilance network, and the health data system. The experts are professors in public health and clinical pharmacology. However, no independent verification of the figures was possible and some data come from self-reported surveillance systems.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Opening by the commission president and introduction of the speakers.
• 02:30Definition of iatrogenesis and its scope: adverse effects, errors, and inappropriate use.
• 08:00Presentation of four data sources: Yathrostat, pharmacovigilance database, HAS reporting, and addictovigilance networks.
• 20:00Description of surveillance actors and the underfunding of pharmacovigilance and addictovigilance centers.
• 32:00Exploration of prevention levels (primary, secondary, tertiary) and the role of software aids and patient involvement.
• 45:00Presentation of the nine recommendations and Q&A with senators on AI, training, and prescription relevance.

• Yathrostat study — National study estimating hospitalizations due to adverse drug effects in French public hospitals.
• Base nationale de pharmacovigilance — Database of reported adverse drug reactions and errors, with 94,000 expertised cases from 2023-2025.
• Rapport du Haut Conseil de la Santé Publique — Main report presented during the hearing, issued in June 2026.
• Rapport sénatorial sur les opioïdes (2025) — Previous Senate report highlighting the capacities of addictovigilance networks.
• EPIPHARE (Groupement d'intérêt public) — Public group exploiting SNDS data for pharmaco-epidemiology, involving ANSM and assurance maladie.

• Rapport sénatorial sur les opioïdes (2025) — Cites the effective detection of tramadol misuse and fentanyl diversion by French addictovigilance centers.
• Étude Yathrostat — Provides the hospitalization and mortality estimates used consistently throughout the hearing.